Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in abnormal uterine bleeding

Ayesha Fatima, Syeda Ayesha Siddiqua
In: International Journal of Research in Medical Sciences · 2024 · vol. 12(7) , pp. 2443–2448 · doi:10.18203/2320-6012.ijrms20241895 · W4400173422
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher

Abstract

Background: Abnormal uterine bleeding is a typical condition for women of reproductive age. It can be painful and uncomfortable, create social disgrace, and have a considerable impact on health-related quality of life. Several studies have shown that ormeloxifene and norethisterone are useful in the treatment of abnormal uterine bleeding, however there is a scarcity of data comparing the efficacy and safety of these medicines. Methods: A prospective comparative study was conducted over 100 women, age group of 30-50 years, attending the gynecology outpatient department with subjective complaints of heavy menstrual bleeding at a tertiary care hospital, in Hyderabad. Group A (n=50) received 60 mg of ormeloxifene and Group B (n=50) received 5mg of norethisterone, respectively. Ethical approval was taken from the institutional ethical committee. Results: 38% aged 41-45, 86% had irregular cycles, 76% reported subjective improvement in group A, and 38% in group B. Group A showed a mean difference of 80.22 in decreasing PBAC score, 0.70 in hemoglobin rise, and 3.5 in decreasing ET, while group B showed 53.70 in PBAC decrease, 0.28 in hemoglobin rise, and 1.76 in endometrial thickness reduction. Both groups have no notable side effects and no significant p value. Conclusions: Reducing PBAC score, subjective improvement, hemoglobin, and endometrial thickness with ormeloxifene and norethisterone works. Ormeloxifene has a far greater effect than norethisterone and has fewer adverse effects.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (13)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK